Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease-Reference-Cited by-同舟云学术

Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease

Published:2016-05-01 Issue:5 Volume:73 Page:561
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Tarawneh Rawan¹,D’Angelo Gina²,Crimmins Dan³,Herries Elizabeth³,Griest Terry³,Fagan Anne M.¹,Zipfel Gregory J.⁴,Ladenson Jack H.³,Morris John C.¹,Holtzman David M.¹

Affiliation:

1. Department of Neurology, Washington University School of Medicine, St Louis, Missouri2Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, Missouri3Charles F. and Joanne Knight Alzheimer Disease Research Center, Wash

2. Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri5Division of Biostatistics, Washington University School of Medicine, St Louis, Missouri

3. Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri

4. Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, Missouri7Department of Neurosurgery, Washington University School of Medicine, St Louis, Missouri

Publisher

American Medical Association (AMA)

Subject

Neurology (clinical)

Cited by 160 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CSF neurogranin levels as a biomarker in Alzheimer’s disease and frontotemporal lobar degeneration: a cross-sectional analysis;Alzheimer's Research & Therapy;2024-09-06

2. Functional Glial Activation Mediates Phenotypic Effects of APOEɛ4 and Sex in Alzheimer’s Disease;Neuroglia;2024-09-05

3. Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: an update of the literature;Expert Review of Neurotherapeutics;2024-09-04

4. Exploring advancements in early detection of Alzheimer's disease with molecular assays and animal models;Ageing Research Reviews;2024-09

5. Common molecular and pathophysiological underpinnings of delirium and Alzheimer’s disease: molecular signatures and therapeutic indications;BMC Geriatrics;2024-08-29